Announced
Completed
RELYPSA INC / GALENICA AG / Acquisition / Public / £1164m
Synopsis
Sale of Relypsa, a biopharmaceutical developer of non-absorbed polymeric drugs for treatment of cardiovascular and renal diseases, to Galenica.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Seller Team (4)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite